A study to evaluate the action of PF-03526299 on asthmatic subjects

• Research type

  Research Study

• Full title

  A randomized, double-blind,third party open, double-dummy, placebo-controlled, 3-way crossover study to determine the duration of action of inhaled doses of PF-03526299 on allergen-induced airway responses in mild asthmatic subjects

• IRAS ID

  69696

• Contact name

  Darren Wilbraham

• Sponsor organisation

  Pfizer Global Research & Development

• Eudract number

  2010-023474-40

• Research summary

  PF-03526299 is an investigational drug being evaluated for the treatment of allergic asthma. The purpose of this study is to find out how long the activity of PF-03526299 lasts after it is inhaled on the lung function of patients with allergic asthma in comparison with placebo (dummy drug) in healthy mild asthmatic volunteers. This study will involve approximately 24 volunteers at up to 2 centres.The study involves 2 screening visits and 3 study periods with a gap of 21 days in between each period over a period of 17 weeks. Each volunteer will be dosed for up to 13 days in each treatment period. There will also be a follow up visit 7 to 14 days after the final dosing.This study will be conducted within the UK.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  10/H0804/92

• Date of REC Opinion

  4 Jan 2011

• REC opinion

  Favourable Opinion